+

WO2003011214A3 - Novel methods and formulations for administration of active agents - Google Patents

Novel methods and formulations for administration of active agents Download PDF

Info

Publication number
WO2003011214A3
WO2003011214A3 PCT/US2002/021646 US0221646W WO03011214A3 WO 2003011214 A3 WO2003011214 A3 WO 2003011214A3 US 0221646 W US0221646 W US 0221646W WO 03011214 A3 WO03011214 A3 WO 03011214A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
administration
active agents
novel methods
conditioning agent
Prior art date
Application number
PCT/US2002/021646
Other languages
French (fr)
Other versions
WO2003011214A2 (en
Inventor
Garfield P Royer
Joseph A Manda
Original Assignee
Royer Biomedical Inc
Garfield P Royer
Joseph A Manda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Royer Biomedical Inc, Garfield P Royer, Joseph A Manda filed Critical Royer Biomedical Inc
Priority to AU2002322424A priority Critical patent/AU2002322424A1/en
Publication of WO2003011214A2 publication Critical patent/WO2003011214A2/en
Publication of WO2003011214A3 publication Critical patent/WO2003011214A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates generally to the production and use of inorganic-conditioning agent complexes for the controlled release of compounds including medicinals. Advantageously, the inorganic used is calcium sulfate and the conditioning agent is calcium stearate.
PCT/US2002/021646 2001-07-31 2002-02-26 Novel methods and formulations for administration of active agents WO2003011214A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002322424A AU2002322424A1 (en) 2001-07-31 2002-02-26 Novel methods and formulations for administration of active agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30859301P 2001-07-31 2001-07-31
US60/308,593 2001-07-31

Publications (2)

Publication Number Publication Date
WO2003011214A2 WO2003011214A2 (en) 2003-02-13
WO2003011214A3 true WO2003011214A3 (en) 2009-06-11

Family

ID=23194577

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/021646 WO2003011214A2 (en) 2001-07-31 2002-02-26 Novel methods and formulations for administration of active agents

Country Status (2)

Country Link
AU (1) AU2002322424A1 (en)
WO (1) WO2003011214A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100379408C (en) * 2003-07-28 2008-04-09 马林克罗特公司 Improved stearate composition and preparation method
PL1680089T3 (en) 2003-10-22 2014-03-31 Lidds Ab Composition comprising biodegradable hydrating ceramics for controlled drug delivery
WO2006023035A2 (en) * 2004-07-28 2006-03-02 Mallinckrodt Inc. Improved stearate composition and method of production thereof
NZ552290A (en) 2006-12-21 2009-05-31 Bomac Research Ltd Tablet fomulation
MX2011003510A (en) 2008-10-02 2011-06-17 Mylan Inc Method of making a multilayer adhesive laminate.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3781268A (en) * 1972-01-27 1973-12-25 Bristol Myers Co Antibiotic derivatives of kanamycin
WO1999015150A1 (en) * 1997-09-22 1999-04-01 Buford Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US6497901B1 (en) * 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3781268A (en) * 1972-01-27 1973-12-25 Bristol Myers Co Antibiotic derivatives of kanamycin
WO1999015150A1 (en) * 1997-09-22 1999-04-01 Buford Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US6497901B1 (en) * 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds

Also Published As

Publication number Publication date
AU2002322424A8 (en) 2009-07-30
AU2002322424A1 (en) 2003-02-17
WO2003011214A2 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
CA2303884A1 (en) Inorganic-polymer complexes for the controlled release of compounds including medicinals
PL367277A1 (en) Methods of making sustained release formulations of oxymorphone related applications
MXPA02012712A (en) N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity.
DE60112974D1 (en) Carbolinderivate
AU2002224927A1 (en) Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
TW200505483A (en) New medicament compositions based on anticholinergically-effective compounds and β-mimetics
HUP0401192A3 (en) Use of photosenzitizing agent for preparation ot, of pharmaceutical composition for treating wounds
WO2003024401A3 (en) Piperizinones as modulators of chemokine receptor activity
DE60216233D1 (en) Carbolinderivate
MXPA03010761A (en) Pharmaceutical combinations.
AU2001266575A1 (en) Chemical compounds
MXPA03002911A (en) Chemical compounds.
WO2002051983A3 (en) Novel compounds and compositions as cathepsin inhibitors
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
WO2002096368A3 (en) Encapsulation of nanosuspensions in liposomes and microspheres
MXPA03010766A (en) Novel compounds and compositions as cathepsin inhibitors.
WO2001098270A3 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2001098269A3 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2001074394A8 (en) New combination of a betablocker and a cholesterol-lowering agent
WO2003011214A3 (en) Novel methods and formulations for administration of active agents
CA2399709A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
CA2445620A1 (en) Tetracyclic compounds as pde5-inhibitors
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
AU2002254930A1 (en) Novel medicament compositions based on anticholinergic agents and endothelin antagonists
WO2002036105A3 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE CH CY DE DK FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载